Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07030868 · ClinicalTrials.gov registry record · Phase 2
A Study of LY3549492 in Adults With Obesity or Overweight With Type 2 Diabetes
A Phase 2 study, sponsored by Eli Lilly and Company.
- Terminated
- Registry status
- Phase 2
- Development phase
- 1
- Enrollment target
NCT07030868 is a Phase 2 study that was terminated before completion, run by Eli Lilly and Company. The registered enrollment target is 1 participants.
The verdict
NCT07030868, a Phase 2 study, was terminated before completion, sponsored by Eli Lilly and Company.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 1 participants
- Enrollment target
Study Summary
The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to evaluate the effects of treatment with LY3549492 compared to placebo in adult participants with obesity or who are overweight with type 2 diabetes. Participation in the study will last about 11 months.
Interventions
- DRUG Placebo
- DRUG LY6249492
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2025-06-19 |
| Est. Completion | 2025-07-29 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07030868
The ClinicalTrials.gov registry entry for NCT07030868 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07030868 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07030868 about?
NCT07030868 is a clinical study titled "A Study of LY3549492 in Adults With Obesity or Overweight With Type 2 Diabetes". The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to evaluate the effects of treatment with LY3549492 compared to placebo in adult participants with obesity or who are overweight with type 2 diabetes. Participation in the study will last about 11 mont...
What is the current status of trial NCT07030868?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2025-06-19. Estimated completion is 2025-07-29.
What interventions are being tested in trial NCT07030868?
The interventions under investigation include: Placebo (DRUG), LY6249492 (DRUG).
Who is sponsoring clinical trial NCT07030868?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.